Member access

4-Traders Homepage  >  Shares  >  Nyse  >  AbbVie Inc    ABBV   US00287Y1091

ABBVIE INC (ABBV)

88
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/20/2015 05/21/2015 05/22/2015 05/26/2015 05/27/2015 Date
65.89(c) 65.65(c) 65.48(c) 66.1(c) 67.38(c) Last
9 955 983 10 553 421 14 041 469 21 034 326 40 778 841 Volume
+0.24% -0.36% -0.26% +0.95% +1.94% Change
More quotes
Financials ($)
Sales 2015 23 305 M
EBIT 2015 9 047 M
Net income 2015 6 586 M
Debt 2015 13 785 M
Yield 2015 3,27%
Sales 2016 26 660 M
EBIT 2016 10 634 M
Net income 2016 7 081 M
Debt 2016 15 166 M
Yield 2016 3,59%
PER 2015 17,59
PER 2016 15,10
EV / Sales 2015 5,07x
EV / Sales 2016 4,48x
Capitalization 104 315 M
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis... 
Sector
Pharmaceuticals
Calendar
07/24Earnings Release
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC
05/27 ABBVIE : Minnesota girl awarded $23M in punitive damages in Depakote suit
05/27 ABBVIE : Reports from AbbVie Inc. Provide New Insights into Endometriosis (Diagn..
05/27 ABBVIE : Galapagos receives transparency notifications
05/27 ABBVIE : St. Louis jury awards Minn. girl $23M for punitive damages in Depakote ..
05/27DJAbbVie Accelerates Share Buybacks
05/27DJAbbVie Accelerates Share Buybacks After Wrapping Up Pharmacyclics Deal
05/27 ABBVIE : Other Events (form 8-K)
05/26 ABBVIE : St. Louis jury awards $15 million in damages in Depakote lawsuit
More news
Sector news : Biopharmaceuticals
05/27DJFDA Clears Two Irritable Bowel Syndrome Treatments
05/27DJFDA Clears Two Treatments for Irritable Bowel Syndrome with Diarrhea
05/27 TAKEDA PHARMACEUTICAL : ZAFATEK® Now Available for the Treatment of Type 2 Diabe..
More sector news : Biopharmaceuticals
4-Traders Strategies on ABBVIE INC 
02/13A likely recovery
More Strategies
News from SeekingAlpha
05/27 DIVIDEND GROWTH INVESTING : The Perfect Portfolio Moving Forward (Part 1)
05/27 Cancer Drug Spending Breaks Through $100B With Immunotherapy Still In Its Inf..
05/27 AbbVie ramps up share buybacks after closing Pharmacyclics deal
05/27 AbbVie's 2-DAA regimen achieves 95% cure rate in Japanese HCV-1b patients
05/27 All Is Well With Neurocrine Biosciences, And It Could Get Better


Comments 
Advertisement
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions